Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Tapped as Next Mitsubishi Tanabe Chief, Hiroaki Ueno Vows to Enrich Pipeline, Accelerate Global Biz
Mitsubishi Tanabe Pharma said on January 14 that Managing Executive Officer Hiroaki Ueno will become its new president on April 1, taking over the reins from Masayuki Mitsuka, who will step aside as a director. At a hastily called press…
To read the full story
Related Article
- With New Chief at Helm, Mitsubishi Tanabe Looks to Boost Presence in Overseas Markets
July 16, 2020
- Mitsuka to Bow Out from Mitsubishi Tanabe Board
April 30, 2020
- Mitsubishi Tanabe to Be Delisted from TSE on February 27
January 20, 2020
- Mitsubishi Chemical to Purchase 197 Million Shares of Mitsubishi Tanabe, Taking Over 90% Ownership
January 9, 2020
- Mitsubishi Chemical to Fully Own Mitsubishi Tanabe to Solidify Healthcare Platform
November 19, 2019
BUSINESS
- Sandoz to Sell, Distribute G-Lasta Biosimilar in Japan
August 26, 2026
- Astellas Starts Global PIII of ASP2138 in Gastric Cancer
August 26, 2026
- Chugai Files Vamikibart in Japan for Uveitic Macular Edema
August 26, 2026
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…